4-Hydroxyacids are products of ubiquitously occurring lipid peroxidation (C 9 , C 6 ) or drugs of abuse (C 4 , C 5 ). We investigated the catabolism of these compounds using a combination of metabolomics and mass isotopomer analysis. 
source of calcium in humans.
We conducted a study on the catabolism of C 4 to C 11 4 -hydroxyacids in perfused rat livers using a combination of metabolomics (17;18) and mass isotopomer analysis 1 (19) . Our metabolomic strategy concentrated on the identification of carboxylic acids and acyl-CoA esters derived from 4-hydroxyacids. The filiation between 4-hydroxyacids and metabolites was demonstrated by conducting experiments with unlabeled and multiply 13 C-or 2 Hlabeled substrates. We demonstrated that the 4-hydroxyacids are degraded by two parallel pathways. The first pathway, which involves 4-hydroxy-4-phosphoacyl-CoAs (4-P-acyl-CoAs) leads to the formation of 3-hydroxyacyl-CoAs which are physiological !-oxidation intermediates. The second pathway is a sequence of !-oxidation, "-oxidation (20;21) , and !-oxidation steps. Via the two pathways, 4-hydroxyacids with 5 or more carbons are degraded to acetyl-CoA, propionyl-CoA and formate.
EXPERIMENTAL PROCEDURES
Materials-Sigma-Aldrich supplied most chemicals, and the following isotopically labeled compounds: 2 H 2 O ( 9 9 % ) , 1 C]hexanoate were prepared by methods to be reported elsewhere. The purity of synthesized compounds was verified by gas chromatography-mass spectrometry and NMR. The lactones of all 4-hydroxyacids were hydrolyzed with 10% excess NaOH at 60°C for 1 hr.
[ 2 H 5 ]Propionyl-CoA was prepared from the acid as described in ref (24) .
Liver perfusions-Livers from male Sprague-Dawley rats were perfused (25) with bicarbonate buffer containing 4 mM glucose and either 4% dialyzed, fatty acid-free, bovine serum albumin (recirculating perfusions) or no albumin (non-recirculating perfusions). After equilibration, 0 to 2 mM of various 4-hydroxyacids, labeled or unlabeled, was added to the perfusate. In some experiments, albuminated perfusate was prepared in 100% 2 H 2 O. Livers were quick-frozen at the end of the experiments.
Analytical Procedures-The concentrations and mass isotopomer distributions of the various acids and 4-hydroxyacids were assayed by gas chromatographymass spectrometry of trimethylsilyl or tertbutyldimethylsilyl derivatives, using analog unlabeled or labeled compounds as internal standards.
For the concentration and labeling pattern of acyl-CoA esters, powdered frozen liver (! 200 mg), spiked with 10 nmol [ 2 H 5 ]propionyl-CoA internal standard was extracted for 1 min with 4 ml of (methanol/water 1:1 containing 5% acetic acid) using a Polytron homogenizer. The supernatant was run on an 3 ml ion exchange cartridge packed with 300 mg of 2-2(pyridyl)ethyl silica gel (Sigma). The cartridge had been pre-activated with 3 ml methanol, then with 3 ml of extraction buffer. The acyl-CoAs trapped on the silical gel cartridge were released with (i) 3 ml of a 1:1 mixture of ammonium formate 50 mM pH 6.3, and methanol (to release the shortand medium-chain acyl-CoAs), then (ii) 3 ml of a 1:3 mixture of ammonium formate 50 mM pH 6.3, and (iii) 3 ml of methanol (to release the mediumand long-chain acyl-CoAs (26)).The combined effluent was dried with nitrogen gas and stored at -80°C until LC-MS analysis.
After dissolving the acyl-CoAs in 100 $l of buffer A (5% acetonitrile in ammonium formate 100 mM, pH 5.0), 40 $l were injected on a Thermo Electron Hypersil GOLD column (150 x 2.1 mm) protected by a guard column (Hypersil Gold 5 $m, 10 x 2.1 mm), in an Agilent 1100 liquid chromatograph. The chromatogram was developed at 0.2 ml/min (i) for 3 min with 98% buffer A and 2% buffer B (95% acetonitrile in ammonium formate 5 mM, pH 6.3) , (ii) from 3 to 25 min with a 2 to 60% gradient of buffer B in buffer A, (iii) from 26 to 31 min with 10% buffer A/90% buffer B, (iv) from 32 to 41 min with a 90% to 2% gradient buffer B in buffer A, and (v) 10 min stabilization with 98% buffer A before the next injection.
The liquid chromatograph was coupled to an 4000 QTrap mass spectrometer (Applied Biosystems, Foster City, CA) operated under positive ionization mode with the following source settings: turbo-ion-spray source at 600 !C under N 2 nebulization at 65 psi, N 2 heater gas at 55 psi, curtain gas at 30 psi, collision-activated dissociation gas pressure was held at high, turbo ion-spray voltage at 5,500 V, declustering potential at 90 V, entrance potential at 10 V, collision energy at 50 V, collision cell exit potential at 10 V. The Analyst software (version 1.4.2; Applied Biosystems) was used for data registration.
The concentration of 4-hydroxybutyrate in mouse blood (27) , the labeling of the acetyl moiety of citrate (28) , a proxy i.e., an indicator of mitochondrial acetyl-CoA, !-hydroxybutyrate (BHB) (22) and of free acetate (29) and formate (29) were assayed as described previously. Exact mass analysis of 4-P-butyryl-CoA and 4-P-pentanoylCoA was run on a Thermo-Finnigan Fourier Transform LTQ mass spectrometer. 31 P-NMR spectra of 4-P-pentanoyl-CoA and of malonyl-CoA standard were run on a 600 MHz Varian Inova equipped with a Broad Band probe. Spectra were acquired for 26 min with a 45 degree pulse width and acquisition time of 1.5 sec with proton decoupling.
Calculations-Correction of measured mass isotopomer distributions for natural enrichment was performed using the CORMAT software (30) . The labeling of the C-1+2 acetyl of BHB, a proxy of mitochondrial acetyl-CoA, was calculated using the mass isotopomer distributions of the whole BHB molecule, and of the C-3+4 fragment of BHB. When mitochondrial acetyl-CoA was only M1 labeled, as from 4-hydroxy- [3- 13 C]nonanoate, the m1 enrichment of the C-1+2 acetyl of BHB was calculated as:
When mitochondrial acetyl-CoA was M1 and M2 labeled, as from 4-hydroxy-[3,4-13 C 2 ]nonanoate, the m1 and m2 enrichments of the C-1+2 acetyl of BHB were calculated assuming that the m2 and m1 labeling ratios of the two acetyls of BHB are identical (Eq. 2)
The total m2 labeling of BHB is expressed as a function of the labeling of its C-3+4 moiety:
is solved for R. R is introduced in Eq. 2 to solve for the m1 and m2 labeling of C-1+2 of BHB.
Data presentation and statistics-We present data from 123 liver perfusion experiments. For a number of conditions, we ran 6 perfusions in the presence of selected unlabeled or 13 C-labeled substrate(s) with the concentration parameters being allowed to vary. The data points shown in the figures represent means of duplicate gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry injections, which differed by <2%. The statistical differences between some profiles was tested using a paired t test (Graph Pad Prism Software, version 3).
RESULTS

Identification of 4-P-acyl-CoAs-
In extracts from rat livers perfused with C 4 to C 11 4-hydroxyacids, LC-MS/MS analysis identified the expected CoA esters of the substrates. These, and all subsequently identified CoA esters, showed the typical transitions (31) from the mass of the parent molecular ion to the product ions at m/z = 428 and 261. These correspond to the nucleoside and pantetheine (minus OH) fragments of CoA (Suppl. Fig 1S, When we compared the fragmentation patterns of 4-hydroxypentanoyl-CoA and of the corresponding new CoA ester, we hypothesized that the unknown ester was 4-hydroxy-4-phosphopentanoyl-CoA (4-P-pentanoyl-CoA) because the singly charged ion transitions A ! C and D ! F (Suppl. Fig 1S) were accompanied by the loss of m/z 98 which is equivalent to phosphoric acid. Corresponding transitions were observed for the u n k n o w n C o A e s t e r d e r i v e d f r o m 4-hydroxybutyrate, identified as 4-P-butyryl-CoA. Also, in experiments with 4-hydroxy-[ To confirm the identity of 4-P-butyryl-CoA and 4-P-pentanoyl-CoA, we isolated these compounds from 10 rat livers perfused with 10 mM 4-hydroxybutyrate or 4-hydroxypentanoate, using semi-preparative HPLC. The isolated esters were analyzed by accurate mass spectrometry which yielded very good matches between the theoretical and measured masses (Supplementary Table 1S ). In addition, the presumed 4-P-pentanoyl-CoA was analyzed by 31 P-NMR ( Fig 1) . Comparison between the 31 P-NMR spectra of the presumed 4-Ppentanoyl-CoA and of a standard of malonyl-CoA showed that it has one extra P atom. This confirmed the identity of 4-P-pentanoyl-CoA.
All the saturated C 4 to C 11 4-hydroxyacids tested formed 4-P-acyl-CoA esters (Fig 2) which accumulated to very different concentrations in the liver. Also, in livers perfused with unlabeled 4-hydroxynonenal or 4-hydroxy-[ 2 H 11 ]nonenal (labeled on the terminal 5 carbons), we identified the corresponding saturated 4-P-acyl-CoAs (Table 1 , to be discussed below).
To test whether phospho-acyl-CoAs are generated from other hydroxyacids, we perfused livers, each with 2 mM of 2-hydroxyacid (C 3 ), 3-hydroxyacids (C 3 to C 5 ), or 5-hydroxyacid (C 5 ). None of these compounds formed a detectable phospho-acyl-CoA.
To gather data that might lead to a hypothesis on the role of 4-P-acyl-CoAs in the metabolism of 4-hydroxyacids, we conducted (i) non-targeted metabolomics analyses on the various liver perfusates, and (ii) detailed assays of acyl-CoA profiles in livers perfused with unlabeled and labeled 4-hydroxyacids.
Experiments with 4-hydroxynonenal-We perfused one liver with recirculating perfusate to which 2 mM [ 2 H 11 ]HNE (labeled on the last 5 carbons) was added at zero time. In the liver tissue and perfusate collected after 2 hr, we identified (Table 1) eight labeled compounds: 4-P-nonanoyl-CoA, four acylCoA esters (C 7 , C 6 , C 5 , C 3 ), 4-hydroxynonanoate, 4-hydroxynonenoate, and 2-hydroxyheptanoate. Table  1 shows the mass isotopomer distributions of these compounds. The same but unlabeled compounds were identified in one liver perfusion with unlabeled 4-hydroxynonenal. The data of Table 1 show that the catabolism of 4-hydroxynonenal leads to compounds containing 7, 6, 5 and 3 carbons. This points to more than one mechanism of degradation because !-oxidation of 4-hydroxynonanoate or 4-hydroxynonenoate would not form the six-carbon hexanoyl-CoA, nor 2-hydroxyheptanoate. Table 1 shows that the mass isotopomer distribution of C 9 metabolites of 4-hydroxy-[ 2 H 1 1 ] n o n e n a l ( 4 -P -n o n a n o y l -C o A , 4 -hydroxynonanoate and 4-hydroxynonenoate) included an unlabeled component (M). The latter was not present in the labeled substrate. Also, in control livers perfused without 4-hydroxynonenal, we could not detect these compounds. It is likely that the metabolism of 4-hydroxy-[ 2 H 11 ]nonenal induced the peroxidation of endogenous lipids resulting in the formation of unlabeled 4-hydroxynonenal. A similar finding has been reported by Cadenas et al who observed the stimulation of the production of ethane and n-pentane by hepatocytes incubated with 2 mM 4-hydroxynonenal (32) .
Metabolomics of metabolites of saturated 4-hydroxyacids released by the perfused rat liver-
To expand on the data of perfusions with 4-hydroxynonenal, we did a metabolomic study of carboxylic acids released by livers perfused with saturated 4-hydroxyacids of various chain length. We identified a pattern of metabolite production which is exemplified in Fig 3 with the products of the metabolism of 4-hydroxyacids with 6, 9 and 11 carbons. With each of these 4-hydroxyacids, we observed the progressive accumulation of (i) a 3-hydroxyacid with the same number of carbons, (ii) a 2-hydroxyacid with 2 carbons less than the starting substrate, and (iii) acids with 2 and 3 carbons less than the starting substrate (not shown on Fig 3) . This suggested the existence of two mechanisms of degradation of 4-hydroxyacids with at least 5 carbons. These mechanisms are outlined in Fig 4 using 4-hydroxynonanoate (compound 1) as the starting substrate. The first mechanism (Fig 4,  pathway A) is the isomerization of 4-hydroxyacylCoA (compound 3) to 3-hydroxyacyl-CoA (compound 10), the normal intermediate of !-oxidation, via 4-P-acyl-CoA and other CoA esters to be described below. This is followed by regular !-oxidation cycles producing (i) acetyl-CoA and propionyl-CoA (in the case of odd-chain 4-hydroxyacids), or (ii) acetyl-CoA (in the case of even-chain 4-hydroxyacids). The second mechanism (Fig 4 , pathway B) , starting at 4-hydroxyacyl-CoA (compound 3), involves one cycle of !-oxidation, followed by one "-oxidation step, and cycles of !-oxidation. Pathway B leads to formate (compound 13, via "-oxidation of 2-hydroxyacyl-CoA and formyl-CoA hydrolysis (21;33)), and either (i) acetyl-CoA + propionyl-CoA (in the case of evenchain 4-OH-fatty acids), or (ii) acetyl-CoA (in the case of odd-chain 4-hydroxyacids with at least 5 carbons). This double mechanism was confirmed by the identification and mass isotopomer distribution of acyl-CoAs and of carboxylic acids formed during the degradation of 4-hydroxyacids labeled with 13 C or 2 H. The evidence is described in the following paragraphs.
Experiments with 4-hydroxy-[3-
13 C]nonanoate and 4-hydroxy- [3,4- 13 C 2 ]nonanoate-We synthesized these labeled compounds because both would lead to the formation of [ (Fig 5) . The mass isotopomer distribution of these compounds is compatible with the scheme presented in Fig 4. We also observed the formation of the unlabeled and labeled 4-ketoacids corresponding to the 4-hydroxyacids (Supplementary Table 2S and Fig 4, compound 2) . Evidence for the reversible interconversion of 4-hydroxyacids and 4-ketoacids, as well as their CoA esters, is presented below.
We also perfused livers with non-recirculating buffer containing increasing concentrations of 4-hydroxy-[3- Figs 8A and 8B show the labeling of acetyl-CoA and of 3 proxies of acetyl-CoA (acetyl moiety of citrate (28;34), C-1+2 acetyl of BHB (35) and free acetate (35;36)) in livers perfused with 4-hydroxy- [3- 13 C]nonanoate (Fig 8A) or 4-hydroxy-[3,4-13 C 2 ]nonanoate (Fig 8B) . In the presence of 4-hydroxy- [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]nonanoate which forms M1 acetylCoA via pathway A (Fig 4) , the M1 labeling of acetyl-CoA and its 3 proxies were similar. In the presence of 4-hydroxy-[3,4-13 C 2 ]nonanoate which forms M2 acetyl-CoA via pathway A and M1 acetylCoA via pathway B (Fig 4) , the M2 labeling of acetyl-CoA and its 3 proxies was 5-6 times higher than the M1 labeling.
The mass isotopomer distribution of acetyl-CoA labeled from 4-hydroxy- [3, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]nonanoate allows to calculate the contributions of pathways A and B to the production of acetyl-CoA from this substrate. Pathways A and B yield 3 and 4 acetyl-CoA, respectively, with one acetyl-CoA being labeled in each pathway. Thus, the contribution of pathway A to acetyl-CoA production is 3 times the m2 enrichment of acetyl-CoA (Fig 8C, middle curve) . Likewise, the contribution of pathway B to acetylCoA is 4 times the m1 enrichment of acetyl-CoA (Fig 8C, lower curve) . The total contribution of 4-hydroxy-[3,4-13 C 2 ]nonanoate to acetyl-CoA plateaued at 55 to 60% (Fig 8C, upper curve) recirculating perfusions with an initial substrate concentration of 2 mM. This rate is similar to the uptake of oleate by the perfused rat liver (37) . Note that part of the carbon derived from the catabolism of 4-hydroxy- [3, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C 2 ]nonanoate is not converted to acetyl-CoA, but is released as shorter carboxylic acids into the perfusate (Supplementary Table 2S ).
We also conducted one recirculating liver perfusion experiment with 2 mM 4-hydroxy-[3-13 C]hexanoate. This compound also led to the accumulation in the perfusate of M1 formate (Fig  5) , 4-ketohexanoate, 3-hydroxyhexanoate, dihydroxyhexanoate (presumably 3,4) and 2-hydroxybutyrate. In the liver, we identified M1 4-Phexanoyl-CoA, 3-hydroxy-4-P-hexanoyl-CoA and butyryl-CoA. This spectrum of labeled compounds is compatible with the scheme shown in Fig 4, Fig 9B) was not M5, but M4 because of additional loss of label in the interconversion of 3-hydroxypentanoate and 3-ketopentanoate (compounds 3 and 4 on Fig 9B) .
The corresponding mass isotopomer profile of metabolites derived from M5 [3,3,5,5,5-2 H 5 ]levulinate, shown in Supplementary Fig 2S, confirms the dual degradation pathway of the substrate, as well as the interconversion of levulinate and 4-hydroxypentanoate.
Because 3-hydroxypentanoate and levulinate were 2 H-labeled, it was not possible to assess whether the lactyl-CoA undergoes "-oxidation to formate in addition to hydrolysis to lactate. This will be investigated with [ Experiments with 4-hydroxybutyrate-In livers perfused with 4-hydroxybutyrate, we detected 4-Pbutyryl-CoA which was present at much lower concentrations than in perfusions with other 4-hydroxyacids (Fig 2, expanded insert) . We did not detect any additional CoA ester which would be part of pathway A or B (Fig 4) (38) . Lastly we could not detect label in acetylCoA. In contrast, we identified M4 succinate and other multi-labeled citric acid cycle intermediates. These are formed by the oxidation of 4-hydroxybutyrate to succinate via succinate semialdehyde, as shown by Kaufman's group (14;39;40) . This is the only known pathway of 4-hydroxybutyrate catabolism. We will present separately a study of the hepatic metabolism of 4-hydroxybutyrate via the citric acid cycle.
Perfusions of 4-hydroxyacids in 100%
2 H 2 O bufferTo gain additional information on the metabolism of 4-hydroxyacids, we perfused 2 livers for 2 hr with recirculating buffer made with 100% 2 H 2 O, and containing 2 mM of unlabeled 4-hydroxyacid with 5 or 9 carbons. The data reveal incorporation of 2 H at multiple levels of 4-hydroxyacid metabolism (Table 2) . First, analysis of the recirculating perfusate sampled just before freeze-clamping the liver at 120 min revealed (i) the presence of mass isotopomers of the substrate with 1 to 3 2 H atoms ( 
Trapping of CoA during the metabolism of 4-hydroxyacids-
The very different accumulations of 4-P-acyl-CoAs in livers perfused with 2 mM of 4-hydroxyacids (Fig 2) hinted that, in some cases, the metabolism of these compounds could lead to substantial trapping of CoA. To gain more insight on this question, we assayed the concentrations of all newly identified CoA esters in livers perfused with increasing concentrations of 4-hydroxyacids. Fig 3S shows the concentrations of a number of CoA esters in livers perfused with increasing concentrations of 4-hydroxyacids with 4 to 9 carbons. For substrates with 5 to 9 carbons, we observed (i) large accumulations of CoA esters formed in the initial metabolism of the substrates (Fig 3S) , (ii) large decreases in free CoA (Fig 10A) , and (iii) large decreases in acetyl-CoA and malonyl-CoA ( Figs  10B and 10C) . Thus, the metabolism of high concentrations of 4-hydroxyacids can lead to substantial CoA trapping which, in some cases, has been linked to metabolic perturbations (41).
Experiments with mice deficient in succinic semialdehyde dehydrogenase-Mice deficient in succinic semialdehyde dehydrogenase (ssadh-/-) were developed (42) as a model to study the biochemical perturbations found in humans with 4-hydroxybutyric aciduria (12) . We assayed the concentrations of 4-P-butyryl-CoA in quick-frozen livers and brains from control, heterozygote and homozygote mice. The concentration of 4-P-butyrylCoA was 9 and 40 times greater in livers and brains of ssadh deficient mice than in livers and brains of control and heterozygote mice (Fig 11) . The high concentration of 4-P-butyryl-CoA in brains of ssadh-/-mice is clearly related to the high concentration of 4-hydroxybutyrate in their plasma (935 ± 97 $M, SE, n = 20; range 264-1683 $M).
The concentration of 4-hydroxybutyrate in the plasma of control and heterozygote mice was undetectable.
DISCUSSION
Our findings demonstrate the existence of the previously unknown phospho-acyl-CoAs which appear to be derived only from 4-hydroxyacids. These 4-P-acyl-CoAs are intermediates in the catabolism of 4-hydroxyacids with at least 5 carbons. The combination of metabolomics and mass isotopomer analysis reveal that the 4-hydroxyacids are metabolized by two pathways. The main pathway (pathway A, Fig 4) involves the isomerization of 4-hydroxyacyl-CoAs to 3-hydroxyacyl-CoA. We propose that this isomerization proceeds via the scheme shown in Fig  4. According to this scheme, the phosphorylation of 4-hydroxyacyl-CoA is followed by dehydrogenation and hydration forming a 3-hydroxy-4-P-acyl-CoA. The latter would be dephosphorylated to the enol form of 3-ketoacyl-CoA which undergoes thiolytic cleavage to a ß-cleaved acyl-CoA. Pathway A (isomerization followed by !-oxidation) is supported by the finding that, in perfusions with 4-hydroxy-[3,4-13 C 2 ]nonanoate (Fig 6) , the following intermediates are doubly-labeled: 4-P-nonanoyl-CoA, 3-hydroxy-4-P-nonanoy l-CoA, 3-hydroxynonanoate, heptanoyl-CoA, heptanoate, the C-1+2 acetyl unit of BHB, and acetyl-CoA.
The accumulation of intermediates in pathway A especially of 4-P-acyl-CoAs (Fig 3S) and the extensive 2 H-labeling of 4-P-acyl-CoAs in perfusions conducted in 100% 2 H 2 O (Table 2 ) suggest that (i) one of the distal steps of pathway A (Fig 4) is limiting, and that (ii) the dehydrogenation and hydration steps are reversible. Thus, our data are compatible with the following sequence of pathway A: 4-hydroxyacyl-CoA ! 4-P-acyl-CoA "! 4-P-2-enoyl-CoA "! 3-hydroxy-4-P-acylCoA ! 3-enol-acyl-CoA "! 3-ketoacyl-CoA "! 3-hydroxyacyl-CoA. The latter undergoes !-oxidation via 3-ketoacyl-CoA.
Pathway B (!-oxidation followed by "-oxidation and !-oxidation) is supported by the finding that, in perfusions with 4-hydroxy-[3,4-13 C 2 ]nonanoate (Fig 6) , (i) the following metabolites are doubly labeled: dihydroxynonanoyl-CoA, dihydroxynonanoate, 2-hydroxyheptanoyl-CoA, 2-hydroxyheptanoate, while (ii) the subsequent metabolites are singly labeled: hexanoyl-CoA, hexanoate, the C-1+2 acetyl unit of BHB and acetylCoA. Through our careful review of the literature, this seems the only example of an "-oxidation step inserted between two !-oxidation cycles. Pathway B is also supported by the release of [ (Fig 5) . 4-Hydroxynonanoate and related compounds are derived from the lipid peroxidation product 4-hydroxynonenal (1), the concentration of which in microsomal membranes can reach mM levels during bursts of lipid peroxidation (43). Although mM concentrations of 4-hydroxynonenal, as used in our study, can have cytotoxic effects (11), our study concentrated on the degradative pathways of the 4-hydroxynonenal carbon skeleton. 4-Hydroxynonenal is converted to 4-hydroxynonenoate 4-hydroxynonanoate and 4-hydroxynonene (for reviews, see (6;8;11) ). The release of [ 3 H]water after injection of 4-hydroxynonenal 3 H-labeled on C-4 or C-2 has been interpreted as demonstrating that part of the substrate undergoes !-oxidation (8) .
Actually, 3 H on C-4 of 4-hydroxynonenal must be released to water at the interconversions of (i) 4-hydroxy-and 4-ketononanoate, and (ii) 4-hydroxyand 4-ketononanoyl-CoA (Fig 4) . 3 H on C-2 of 4-hydroxynonenal must be released to water in the first !-oxidation cycle of pathway B, and in the reversible dehydrogenation and hydration steps of pathway A (4-P-acyl-CoA "! 4-P-2-enoyl-CoA "! 3-hydroxy-4-P-acyl-CoA ). Our data demonstrate the complete oxidation of 4-hydroxynonenal by following the label from 4-hydroxy-[ 2 H 11 ]nonenal down to propionyl-CoA (Table 1) . Also, our experiments with 4-hydroxy-[3,4-13 C 2 ]nonanoate (Figs 4-8) demonstrate the complete oxidation of the carbon skeleton of 4-hydroxynonenal to acetyl-CoA, propionyl-CoA and formate.
The trapping of CoA in intermediates of the degradation of 4-hydroxyacids with 5 or more carbons (Fig 3S) results in the decrease in the liver concentration of free CoA, acetyl-CoA and malonylCoA (Fig 11) . Trapping of CoA by the metabolism of some drugs has been implicated in the deleterious effects of the drugs (44). Also, in some inborn errors of metabolism, the accumulation of CoA esters has been implicated in the physiopathology of the diseases (41). However, in the case of 4-hydroxynonanoate, this trapping of CoA does not prevent the substrate (i) to be taken up at a rate similar to that of a long-chain fatty acid like palmitate, and (ii) to contribute 55 to 60% of acetylCoA produced by the liver. However, in some situations the trapping of CoA by the metabolism of 4-hydroxyacids could result in metabolic perturbations.
Note that some of the reactions of 4-hydroxynonanoate metabolism probably occur in peroxisomes. This is the site of fatty acid "-oxidation (20) which, in the present case, forms [ 13 C]formate from 4-hydroxynonanoate labeled on C-3. Given the low labeling of acetyl-CoA and its proxies formed from 4-hydroxy [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]nonanoate (Fig 8A) , it is likely that pathway B is peroxisomal, and pathway A is mitochondrial.
Our data on the accumulation of 4-P-butyrylCoA in the brain and liver of mice unable to convert 4-hydroxybutyrate to succinate (Fig 10) suggest that 4-P-butyryl-CoA may contribute to the perturbation of brain metabolism in these mice who experience severe epileptic seizures (42). Also, 4-P-butyrylCoA may contribute to the severe mental retardation of patients with 4-hydroxybutyric aciduria (12) . Lastly, 4-P-butyryl-CoA may be implicated in acute mental dysfunction of subjects who ingested 4-hydroxybutyrate. Similar mental dysfunction is likely to be caused by the accumulation of 4-Pp e n t a n o y l -C o A i n s u b j e c t s i n g e s t i n g 4-hydroxypentanoate as an alternate drug of abuse to 4-hydroxybutyrate (16 (17) . Note that for even-chain 4-hydroxyacids with at least six carbons, pathway A leads to acetyl-CoA, while pathway B leads to acetyl-CoA, propionyl-CoA and formate. Fig 4) . **: M2 dihydroxynonanoyl-CoA is an intermediate of the !-oxidation cycle between compounds 3 and 11 (Fig 4) . ***: M2 diketononanoyl-CoA is an intermediate of the !-oxidation of compound 4 to compound 11, without passing by compound 3 (Fig 4) . Note that the two substrates were unlabeled when added to the labeled buffer. All data are corrected for natural enrichment. Also the mass isotopomer distributions of the 4-OH-acyl-CoAs and 4-phospho-acyl-CoAs have been corrected for the incorporation of 
